Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | KDM1A | O60341 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422415 | 1.00 | CYP3A4 (0.79) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL2112475 | 0.89 | CYP3A4 (1.00) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL725581 | 0.89 | CYP3A4 (1.00) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL2111363 | 0.89 | CYP3A4 (1.00) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL724765 | 0.88 | CYP3A4 (0.75) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL3421761 | 0.82 | CYP3A4 (0.63) | CYP3A4KDM1AMAOAMAOBNR3C1 | |
| SCHEMBL2111644 | 0.78 | CYP3A4 (0.69) | CYP3A4KDM1AMAOAMAOBNR3C2 | |
| SCHEMBL3423335 | 0.77 | CYP3A4 (0.57) | CYP3A4KDM1ANR3C1PGRNR3C2 | |
| SCHEMBL726323 | 0.74 | CYP3A4 (0.64) | CYP3A4KDM1ANR3C2BRD4EP300 | |
| SCHEMBL3478670 | 0.73 | CYP3A4 (0.56) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158803-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LEE EUN KYUNG | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, RRM2B | CYP3A4 417/4885KDM1A 1567/4885MAOA 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.